Technological projects portfolio
DTR8
Therapeutic protein for the treatment of a rare kidney disease, crescentic glomerulonephritis
Investment: €748k
Scope: Healthcare
Scientific field(s): Biology and medicinal chemistry
Institution(s): CEA - Inserm - AP-HP - Université de Paris
Development: Start-up in progress/completed
USE CASES
Rapidly Progressive Glomerulonephritis (RPGN) is a very rare auto-immune disease (less than 10 cases per million, per year worldwide) that leads to irreversible loss of renal function through a rapid decline in the glomerular filtration rate. Depending on the type of RPGN, the mortality rates can reach up to 50%.
No specific treatment exists. Combinations of immunosuppressants and anti-inflammatory drugs (corticosteroids) are used but are not very effective and lead to a degradation in quality of life for patients due to their side effects and due to persistent renal dysfunction.
ADVANTAGES
The DTR8 project aims to develop a therapeutic protein that acts specifically on renal cells: the action is immediate and the recovery of renal function is possible.
APPLICATIONS
Patients suffering from type 3 RPGN receiving first-line treatment or in the event of relapse.